Eureka Therapeutics Inc.
13
3
3
2
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 100/100
30.8%
4 terminated/withdrawn out of 13 trials
33.3%
-53.2% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
T-Cell Therapy (ECT204) in Adults With Advanced HCC
Role: lead
Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell Lymphoma
Role: collaborator
Study of ET140203 T Cells in Adults With Advanced Hepatocellular Carcinoma (ARYA-1)
Role: lead
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
Role: collaborator
ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma
Role: lead
Study of ET140202 T Cells in Adults With Advanced Hepatocellular Carcinoma
Role: lead
ET1402L1-ARTEMIS™2 T Cells in Alpha Fetoprotein (AFP) Expressing Hepatocellular Carcinoma
Role: collaborator
Clinical Study of ET190L1 ARTEMIS™ in Relapsed, Refractory B Cell Lymphoma
Role: lead
ET 140202 -T Cell Combined With TAE or Sorafenib in the Treatment of Liver Cancer
Role: collaborator
Clinical Study of ET1402L1-CAR T Cells in AFP Expressing Hepatocellular Carcinoma
Role: collaborator
ET190L1-ARTEMIS™ T Cells in Relapsed, Refractory B Cell Leukemia and Lymphoma
Role: collaborator
Study of ET190L1 ARTEMIS™ T Cells in Relapsed and Refractory CD19+ Non-Hodgkin's Lymphoma
Role: lead
Clinical Study of ET019002-T Cell Therapy for Refractory/Relapsed B-Cell Malignancies
Role: collaborator
All 13 trials loaded